Evidence map›Paper›PMID 37715247›Full record

ArticleActa neuropathologica communications2023

Proteomic analysis across patient iPSC-based models and human post-mortem hippocampal tissue reveals early cellular dysfunction and progression of Alzheimer's disease pathogenesis.

Yuriy Pomeshchik, Erika Velasquez, Jeovanis Gil, Oxana Klementieva, Ritha Gidlöf, Marie Sydoff, Silvia Bagnoli, Benedetta Nacmias, Sandro Sorbi, Gunilla Westergren-Thorsson and 3 more

Open access · goldAbstract read
In one paragraph

Article in Acta neuropathologica communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Neurodegeneration: 2024 update.Free neuropathology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 3 countries.

Yuriy PomeshchikiPSC Laboratory for CNS Disease Modelling, Department of Experimental Medical Science, BMC D10, Lund University, 22184, Lund, Sweden. yuriy.pomeshchik@med.lu.se.
Erika VelasqueziPSC Laboratory for CNS Disease Modelling, Department of Experimental Medical Science, BMC D10, Lund University, 22184, Lund, Sweden.
Jeovanis GilClinical Protein Science & Imaging, Department of Biomedical Engineering, BMC D13, Lund University, 22184, Lund, Sweden.
Oxana KlementievaStrategic Research Area MultiPark, Lund University, 22184, Lund, Sweden.
Ritha GidlöfLund University BioImaging Centre, Faculty of Medicine, Lund University, 22142, Lund, Sweden.
Marie SydoffLund University BioImaging Centre, Faculty of Medicine, Lund University, 22142, Lund, Sweden.
Silvia BagnoliLaboratorio Di Neurogenetica, Dipartimento Di Neuroscienze, Psicologia, Area del Farmaco e Salute del Bambino- NEUROFARBA, Università degli Studi di Firenze, 50134, Florence, Italy.
Benedetta NacmiasLaboratorio Di Neurogenetica, Dipartimento Di Neuroscienze, Psicologia, Area del Farmaco e Salute del Bambino- NEUROFARBA, Università degli Studi di Firenze, 50134, Florence, Italy.
Sandro SorbiLaboratorio Di Neurogenetica, Dipartimento Di Neuroscienze, Psicologia, Area del Farmaco e Salute del Bambino- NEUROFARBA, Università degli Studi di Firenze, 50134, Florence, Italy.
Gunilla Westergren-ThorssonDepartment of Experimental Medical Science, BMC C12, Faculty of Medicine, Lund University, 22142, Lund, Sweden.
Gunnar K GourasStrategic Research Area MultiPark, Lund University, 22184, Lund, Sweden.
Melinda RezeliClinical Protein Science & Imaging, Department of Biomedical Engineering, BMC D13, Lund University, 22184, Lund, Sweden.
Laurent RoyboniPSC Laboratory for CNS Disease Modelling, Department of Experimental Medical Science, BMC D10, Lund University, 22184, Lund, Sweden. laurent.roybon@vai.org.
Lund University · SEUniversity of Florence · ITDon Carlo Gnocchi Foundation · ITVan Andel Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The hippocampus is a primary region affected in Alzheimer's disease (AD). Because AD postmortem brain tissue is not available prior to symptomatic stage, we lack understanding of early cellular pathogenic mechanisms. To address this issue, we examined the cellular origin and progression of AD pathogenesis by comparing patient-based model systems including iPSC-derived brain cells transplanted into the mouse brain hippocampus. Proteomic analysis of the graft enabled the identification of pathways and network dysfunction in AD patient brain cells, associated with increased levels of Aβ-42 and β-sheet structures. Interestingly, the host cells surrounding the AD graft also presented alterations in cellular biological pathways. Furthermore, proteomic analysis across human iPSC-based models and human post-mortem hippocampal tissue projected coherent longitudinal cellular changes indicative of early to end stage AD cellular pathogenesis. Our data showcase patient-based models to study the cell autonomous origin and progression of AD pathogenesis.

Indexed as

Alzheimer DiseaseInduced Pluripotent Stem CellsAnimalsAutopsyHippocampusHumansMiceProteomicsAlzheimer’s diseaseHippocampal spheroidsHuman post-mortem tissueInduced pluripotent stem cellsIntracerebral transplantationProteomic analysis

Identifiers

PMID37715247
PMCPMC10504768
OpenAlexW4386768297

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.